Amyloidosis; Heart (Manifestation), Arrhythmogenic Right Ventricular Cardiomyopathy, Dilated Cardiomyopathies, Giant Cell Myocarditis, Hypertrophic Cardiomyopathy, Myocarditis, Restrictive Cardiomyopathy, Sarcoidosis With Myocarditis
Conditions
Brief summary
This is a joint project by Sahlgrenska University Hospital: Sahlgrenska, Östra and Mölndal. Our objective is to diagnose and map patients with well phenotyped cardiomyopathies (CMP) including in depth clinical and molecular phenotyping to enable earlier and specific treatment. The project will serve as: 1. resource for diagnostic and therapeutic trials 2. common biomaterial bank 3. resource for detailed molecular analyses on patients' biomaterials and patient specific symptoms and examination results
Interventions
None listed
Sponsors
Sahlgrenska University Hospital
Göteborg University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients with primary cardiomyopathies including hereditary and inflammatory dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, left ventricular non-compaction cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, myocarditis, giant cell myocarditis, sarcoidosis and amyloidosis engaging the heart
Exclusion criteria
* Patient with other preexisting cardiac diseases such as significant valvular, ischemic or pericardial disease before they receive a cardiomyopathy diagnose * patients \< 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to disease progression | 2018-2028 |
Other
| Measure | Time frame |
|---|---|
| Progression in biomarker NT-proBNP | 2018-2028 |
| Changes over time in presence of autoantibodies | 2018-2028 |
| Disease activity evaluated by positron-emissions-tomography computed tomography (PET-CT) | 2018-2028 |
| Disease activity evaluated by magnetic resonance imaging (MRI) | 2018-2028 |
Countries
Sweden
Outcome results
None listed